490 Arsenal Way
Suite120
Watertown, MA 02472
United States
617 231 0700
https://www.c4therapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 145
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Andrew J. Hirsch M.B.A. | CEO, President & Director | 971k | N/A | 1971 |
Dr. Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board | 39.03k | N/A | 1951 |
Mr. Scott N. Boyle M.B.A., Ph.D. | Chief Business Officer | 672.78k | N/A | 1978 |
Dr. Nathanael S. Gray Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | N/A |
Mr. Mark Mossler | Chief Accounting Officer | N/A | N/A | 1973 |
Ms. Jolie M. Siegel J.D. | Chief Legal Officer & Corporate Secretary | 610.4k | 1.06M | 1977 |
Ms. Kelly A. Schick | Chief People Officer | N/A | N/A | 1980 |
Dr. Isabel Chiu Ph.D. | Senior Vice President of Strategic Alliances & Business Development | N/A | N/A | N/A |
Dr. Christopher Nasveschuk | Senior Vice President of Chemistry | N/A | N/A | N/A |
Mr. Roy Pollock Ph.D. | Senior Vice President of Biological Sciences | N/A | N/A | N/A |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
C4 Therapeutics, Inc.’s ISS governance QualityScore as of 29 April 2024 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 8; Compensation: 9.